Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,641 to 1,660 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A multi-omics machine learning framework in predicting the recurrence and metastasis of patients with pancreatic adenocarcinoma. | Front Microbiol | 2022 | 36406449 | PubTator, text mining | PubMed |
| N6-methyladenosine (m6A) RNA methylation mediated by methyltransferase complex subunit WTAP regulates amelogenesis. | J Biol Chem | 2022 | 36403857 | PubTator, text mining | PubMed |
| HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma. | J Transl Med | 2022 | 36401285 | PubTator, text mining | PubMed |
| METTL3-mediated m6A modification stabilizes TERRA and maintains telomere stability. | Nucleic Acids Res | 2022 | 36399511 | PubTator, text mining | PubMed |
| N6-methyladenosine modification governs liver glycogenesis by stabilizing the glycogen synthase 2 mRNA. | Nat Commun | 2022 | 36396934 | PubTator, text mining | PubMed |
| The biological function of m6A methyltransferase KIAA1429 and its role in human disease. | PeerJ | 2022 | 36389416 | PubTator, text mining | PubMed |
| The development and validation of a m6A-lncRNAs based prognostic model for overall survival in lung squamous cell carcinoma. | J Thorac Dis | 2022 | 36389308 | PubTator, text mining | PubMed |
| Construction and validation of a m6A RNA methylation and ferroptosis-related prognostic model for pancreatic cancer by integrated bioinformatics analysis. | J Gastrointest Oncol | 2022 | 36388690 | PubTator, text mining | PubMed |
| Identification of a five m6A-relevant mRNAs signature and risk score for the prognostication of gastric cancer. | J Gastrointest Oncol | 2022 | 36388685 | PubTator, text mining | PubMed |
| The roles of RNA N6-methyladenosine in esophageal cancer. | Heliyon | 2022 | 36387447 | PubTator, text mining | PubMed |
| WFDC21P promotes triple-negative breast cancer proliferation and migration through WFDC21P/miR-628/SMAD3 axis. | Front Oncol | 2022 | 36387210 | PubTator, text mining | PubMed |
| Circular RNAs as diagnostic biomarkers for gastric cancer: A comprehensive update from emerging functions to clinical significances. | Front Genet | 2022 | 36386850 | PubTator, text mining | PubMed |
| Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma. | BMC Bioinformatics | 2022 | 36384423 | PubTator, text mining | PubMed |
| Early recruitment of PARP-dependent m8A RNA methylation at DNA lesions is subsequently accompanied by active DNA demethylation. | RNA Biol | 2022 | 36382943 | PubTator, text mining | PubMed |
| Detecting RNA modification using direct RNA sequencing: A systematic review. | Comput Struct Biotechnol J | 2022 | 36382183 | PubTator, text mining | PubMed |
| tRNA-derived fragment tRF-1001: A novel anti-angiogenic factor in pathological ocular angiogenesis. | Mol Ther Nucleic Acids | 2022 | 36381574 | PubTator, text mining | PubMed |
| The RNA demethylase ALKBH5 promotes the progression and angiogenesis of lung cancer by regulating the stability of the LncRNA PVT1. | Cancer Cell Int | 2022 | 36376862 | PubTator, text mining | PubMed |
| Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting. | Exp Hematol Oncol | 2022 | 36371254 | PubTator, text mining | PubMed |
| Matr3 reshapes m6A modification complex to alleviate macrophage inflammation during atherosclerosis. | Clin Immunol | 2022 | 36368640 | PubTator, text mining | PubMed |
| Identifying Prognostic Biomarkers Related to m6A Modification and Immune Infiltration in Renal Cell Carcinoma. | Genes (Basel) | 2022 | 36360294 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=83